NL-OMON33990已完成3 期
A multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, Phase III study to assess the effects of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertension - SERAPHI
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Signed informed consent prior to initiation of any study mandated procedure.
- •2. Patients with symptomatic pulmonary arterial hypertension (PAH) in modified WHO functional class II to IV.
- •3. Patients with the following types of PAH belonging to groups 1.1 to 1.3 of the Venice classification:
- •a. Idiopathic (IPAH);
- •b. Familial (FPAH); or
- •c. Related to:
- •i. Collagen vascular disease;
- •ii. Simple, congenital systemic-to-pulmonary shunts at least 1 year post surgical repair;
- •iii. HIV infection; or
- •iv. Drugs and toxins.
- •4. PAH diagnosis confirmed by hemodynamic evaluation performed prior to randomization and showing all of the following:
- •a. Mean pulmonary artery pressure (mPAP) > 25 mmHg at rest;
- •b. Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure (LVEDP) <= 15 mmHg; and
- •c. Pulmonary vascular resistance (PVR) at rest >= 320 dyn-sec/cm5.
- •* For patients who participate in the pharmacokinetic/ pharmacodynamic substudy, hemodynamic evaluation must have been performed within 3 months prior to randomization.
- •* For all other patients, hemodynamic evaluation must have been performed within 1 year prior to randomization.
- •5. 6-minute walk distance (6MWD) >= 50 m.
- •6. Men or women >= 12 years of age (women of childbearing potential must have a negative pre-treatment serum pregnancy test and must use a reliable method of contraception).
排除标准
- •1. PAH associated with portal hypertension, thyroid disorders, glycogen storage disease, Gaucher**s disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders or splenectomy.
- •2. PAH associated with non corrected simple congenital systemic-to-pulmonary shunts, and combined and complex systemic-to-pulmonary shunts, corrected or non corrected.
- •3. PAH associated with significant venous or capillary involvement (PCWP > 15 mmHg), known pulmonary veno-occlusive disease, and pulmonary capillary hemangiomatosis.
- •4. Persistent pulmonary hypertension of the newborn.
- •5. Pulmonary Hypertension belonging to groups 2 to 5 of the Venice classification.
- •6. Moderate to severe obstructive lung disease: forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) < 70% and FEV1 < 65% of predicted value after bronchodilator administration.
- •7. Moderate to severe restrictive lung disease: total lung capacity (TLC) < 60% of predicted value.
- •8. Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C.
- •9. Estimated creatinine clearance < 30 mL/min
- •10. Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 1.5 times the upper limit of normal.
- •11. Hemoglobin < 75% of the lower limit of the normal range.
- •12. Systolic blood pressure < 100 mmHg.
- •13. Acute or chronic physical impairment (other than dyspnea), limiting the ability to comply with study requirements.
- •14. Pregnant or breast-feeding.
- •15. Known concomitant life-threatening disease with a life expectancy < 12 months.
- •16. Body weight < 40 kg.
- •17. Any condition that prevents compliance with the protocol or adherence to therapy.
- •18. Recently started (< 8 weeks prior to randomization) or planned cardio-pulmonary rehabilitation program based on exercise.
- •19. Treatment with endothelin receptor antagonists (ERAs) within 3 months prior to randomization.
- •20. Systemic treatment within 4 weeks prior to randomization with cyclosporine A or tacrolimus, everolimus, sirolimus (calcineurin or mTOR inhibitors).
- •21. Treatment with CYP3A inducers within 4 weeks prior to
- •randomization.
- •22. Known hypersensitivity to drugs of the same class as the study drug, or any of their excipients.
- •23. Planned treatment, or treatment, with another investigational drug within 1 month prior to randomization.
研究者
相似试验
进行中（未招募）
1 期
A research study to study the effects of a new oral drug called lucerastat in adults with Fabry diseaseFabry diseaseMedDRA version: 20.0Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-003369-85-NLIdorsia Pharmaceuticals Ltd99
进行中（未招募）
不适用
A multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, Phase III study to assess the effects of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertension - SERAPHITo assess the effects of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertensionMedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionEUCTR2007-002440-14-DEActelion Pharmaceuticals Ltd.700
进行中（未招募）
不适用
A multicenter, double-blind, randomized, placebo-controlled, two-arm parallel-group study of BGG492 as monotherapy in individuals with refractory partial seizures undergoing inpatient evaluation for epilepsy surgeryMedDRA version: 9.1Level: LLTClassification code 10061334Term: Partial seizuresEpilepsyEUCTR2008-005065-64-DEovartis Pharma Services AG
进行中（未招募）
1 期
A research study to study the effects of a new oral drug called lucerastat in adults with Fabry diseaseFabry diseaseMedDRA version: 20.0Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-003369-85-GBIdorsia Pharmaceuticals Ltd99
进行中（未招募）
不适用
A multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and tolerability of AVE5530 when added to ongoing stable statin therapy at high doses in patients with severe primary hypercholesterolemiaPrimary HypercholesterolemiaMedDRA version: 11.0Level: LLTClassification code 10060375Term: <Manually entered code. Term in E.1.1>EUCTR2008-002849-23-BESanofi-Aventis Recherche & Développement668